Viscum Album for TNBC on Adjuvant Pembrolizumab

PHASE4RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

March 19, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2028

Conditions
Breast CancerTriple Negative Breast Cancer
Interventions
DRUG

viscum album

"Active Ingredient: Viscum album Excipients: Ascorbic acid, disodium phosphate dihydrate, monosodium phosphate monohydrate Formulation: Injectable solution contained in a colorless ampoule; the solution is colorless to pale yellow and clear.~Manufacturer: LB Abnoba Co., Ltd. Dosage and Administration: Administered subcutaneously three times per week, with dose escalation according to the following protocol."

Trial Locations (1)

082-10414

RECRUITING

Ilsan Cha Hospital, Goyang-si

All Listed Sponsors
lead

Ilsan Cha hospital

OTHER